FundaMental Pharma is engaged in pioneering research around a breakthrough molecular mechanism that allows to safely counteract glutamate neurotoxicity (also known as excitotoxicity) by specifically targeting the interface between NMDA receptors and TRPM4 channels with small molecule TwinF interface inhibitors (Yan et al., Science 2020). TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. Our initial focus is on amyotrophic lateral sclerosis (ALS). The applicability of our molecules extends to a range of neurogenerative disorders including Alzheimer’s disease (AD)." title="" class="btn" data-container="body" data-html="true" data-id="235450" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="FundaMental Pharma"> 829
Activities
Technologies
Entity types
Location
Im Neuenheimer Feld 582, 69120 Heidelberg, Germany
Heidelberg
Germany
Employees
Scale: 2-10
Estimated: 11
Engaged catalyst
0Added in Motherbase
1 year agoWe Fight Neurodegeneration
FundaMental Pharma is engaged in pioneering research around a breakthrough molecular mechanism that allows to safely counteract glutamate neurotoxicity (also known as excitotoxicity) by specifically targeting the interface between NMDA receptors and TRPM4 channels with small molecule TwinF interface inhibitors (Yan et al., Science 2020). TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. Our initial focus is on amyotrophic lateral sclerosis (ALS). The applicability of our molecules extends to a range of neurogenerative disorders including Alzheimer’s disease (AD).